Tolfenamic acid is clinically indicated for a variety of inflammatory conditions in various animal species. Its properties, which include antiinflammatory, analgesic, antipyretic, and anti-endotoxaemic effects, may also prove beneficial across different animal species. [1, 2] The most prevalent adverse effect associated with NSAIDs is their tendency to cause gastric or intestinal ulceration, which can occasionally lead to anemia due to the resulting blood loss. [3, 4, 5] Changes in haematological parameters and toxic effects have been noted in rats subjected to long-term treatment with specific NSAIDs such as diclofenac sodium and ibuprofen. [6, 7] This study was carried out to assess the safety of tolfenamic acid (4 mg/kg)
after daily intramuscular injection for a duration of 14 days in wistar rats.
Tolfenamic acid in its pure base form, reagents necessary for hematology and biochemistry analysis were outsourced. Tolfenamic acid was prepared in a 30% Labrasol solution within phosphate buffer saline for dosage administration.
The research involved 20 adult, healthy male and female wistar rats. The rats were kept in individually ventilated cages under standard laboratory conditions at the experimental animal room. Rats aged 6-8 weeks were chosen following a thorough physical and behavioral assessment. The live body weight of the rats was maintained within ± 20% of the average body weight for each sex at the time of randomization. Food and water were made available ad libitum.
The approval of study protocol was obtained from the Institutional Animal Ethics Committee.
All animals were acclimatized to the experimental conditions for duration of seven days prior to grouping and dosing. A total of twenty animals were divided into two groups, each consisting of 5 male and 5 female animals. The doses were calculated based on the body weight of the animals and were administered according to the concentration strength of the formulation. Tolfenamic acid (4 mg/kg) was administered intramuscularly in the thigh region of the animals at 24-hour intervals for a period of 14 days. Group I acted as the control group and received only the vehicle, while group II was administered tolfenamic acid.
Blood samples were obtained from the retro-orbital plexus on day 0 (prior to drug administration), as well as on the 7th and 14th days for hematological and serum biochemical analysis under anesthetic conditions. Blood samples intended for serum biochemical analysis were permitted to clot and subsequently centrifuged after which the serum was collected. The hematological and biochemical parameters were evaluated using an automatic hematology and biochemical analyzer respectively.
Body weight was recorded daily throughout the study period, and feed consumption was documented at weekly intervals. All animals were humanely sacrificed on day 15, and a postmortem examination was conducted in a confined, disinfected laboratory to assess the presence or absence of gross pathological lesions. For histopathological analysis, samples from various organs were collected in 10% formalin and preserved for further processing. The relative organ weights were also recorded. The tissues were processed for histopathological evaluation.
The data collected regarding body weight, hematological parameters, serum biochemical parameters, feed consumption, and organ weights were subjected to statistical analysis. The results were presented as mean, standard error of the mean (SEM), and percentage change.
In the current study, neither male nor female animals from any group exhibited symptoms linked to the 14-day intramuscular administration of tolfenamic acid.
Throughout the study duration, no animals were found dead in any of the groups. There were no statistically significant (p < 0.05) differences in body weight gain between male and female animals in the treatment group when compared to their respective control group by the conclusion of the treatment period.
Feed intake among male and female animals treated with tolfenamic acid showed no significant changes in comparison to control animals.
The mean values of all hematological parameters for male and female rats in the treatment group did not show any significant differences when compared to the corresponding values recorded in the control animals. The mean values of serum glucose, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, total
bilirubin, total protein, albumin, globulin, creatinine, urea, and uric acid were also not significantly different from those of the control group.
The post-mortem examinations of all animals from the various groups were conducted on the 14th day of treatment. During the gross pathological examination, no abnormal lesions were detected in the liver, kidneys, stomach, intestines, heart, spleen, or muscles at the injection site that could be attributed to the 14-day administration of tolfenamic acid in the animals. No ulcerative lesions in the stomach or duodenum were identified in any of the animals. The absolute and relative organ weights for the adrenals, heart, kidneys, liver, spleen, and thymus of both male and female animals from the control and treatment groups were recorded at the time of necropsy. There were no changes in the absolute and relative organ weights in the treated animals compared to the control group.
Histological changes were not noted, except for the muscle at the injection site in one or two animals from each group, while histopathological changes were absent in any of the organs of both groups. The minor damage observed at the injection site in a few animals from both groups may be attributed to the vehicle effect.
Plasma ALT activity, accompanied by significant histopathological changes has been documented following repeated daily administration of mefenamic acid in mice. [8] Additionally, gastrointestinal ulcers, hepatopathy, and nephropathy have been noted with ketoprofen long term use at high dose. [9] Such changes were not observed in the animal model treated with tolfenamic acid in the current study.
Repeated administration of tolfenamic acid in wistar rats was found safe based on evaluation result of haematological and serum biochemical parameters (Blood glucose, AST, ALT, ALP, total bilirubin, serum total protein, serum albumin, globulin, creatinine, urea and uric acid) as well as gross lesions and histopathology of liver, kidney, stomach, intestine, heart, spleen, joint cartilage and muscles of injection site. Significant changes in absolute and relative organ weights in tolfenamic acid treated rats have not been observed. Tolfenamic acid can be administered repeatedly by intramuscular injection without side effects.
The authors express their sincere gratitude to the head of department for his continuous support and encouragement throughout this work.
No funding was received for this study.
The authors declare no conflicts of interest.
[1] Rejholec V, Vapaatalo H, Tokola O and Gothoni G. A comparative, double-blind study on tolfenamic acid in the treatment of rheumatoid arthritis. Scandin J Rheumatol. 1979: 24:13-16.
[2] Ahmed S, Sheraz MA, and Ahmad I. Tolfenamic Acid. Profiles Drug Subst Excip Relat Methodol. 2018: 43: 255-319.
[3] Tai FWD, McAlindon ME. Non-steroidal anti-inflammatory drugs and the gastrointestinal tract. Clin Med. 2021:21(2): 131-134.doi:10.7861/clinmed.2 021-0039.
[4] Gabriel SE, Jaakkimainen L and Bombardier C. Risk for serious gastrointestinal complications related to use of non-steroidal anti-inflammatory drugs: A meta analysis. Ann Intern Med. 1991: 328:1313-1316.
[5] Figueras A, Capella D, Castel JM and Laorte JR. Spontaneous reporting of adverse drug reactions to NSAID. A report from the Spanish system of pharmacovigilance, including an early analysis of topical and enteric coated formulations. Eur J Clin Pharmacl. 1994: 47:297-303.
[6] Orinya OA, Adenkola AY and Ogbe R J. Haematological and biochemical studies on the effect of diclofenac sodium on wistar rattus norvegicus. International Journal of Biological and Chemical Sciences. 2017: 10(5), 2231-2242.
[7] Jonah SA, Lucky LN, Cecilia AO. Evaluation of Toxicological Profile of Ibuprofen in Wistar Albino Rats. Am. J. Biomed. Sci. 2014: 6(1), 32-40; doi: 10.5099/aj140100032
[8] Somchit N, Sanat F, Gan EH, Shahrin IA and Zuraini A. Liver injury induced by the non-steroidal anti-inflammatory drug mefenamic acid. Singapore Med J. 2004: 45:530-532.
[9] Luna SP, Basilio AC, Steagall PV, Machado LP, Moutinho FQ, Takahira RK and Brandao CV. Evaluation of adverse effects of long-term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen, and meloxicam in dogs. Am J Vet Res. 2007: 68: 258-264.
IJBMR -ISSN: 0976:6685. ©Copyright 2026 This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Published by BioMedSciDirect Publications